Alpha 2.0
Login Register
» Authors » L Vuitton

L Vuitton

Explore the profile of L Vuitton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 421
Followers 0
Related Specialties
Gastroenterology
Pharmacology
Radiology
Top 10 Co-Authors
L Peyrin-Biroulet
A Amiot
S Nancey
D Laharie
J Filippi
R Altwegg
P Marteau
M Serrero
M Nachury
Y Bouhnik
Published In
J Crohns Colitis
Aliment Pharmacol Ther
Gut
Clin Radiol
United European Gastroenterol J
Affiliations
Soon will be listed here.
Recent Articles
1.
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study
Hupe M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, et al.
Dig Liver Dis . 2024 Jan; 56(8):1312-1318. PMID: 38281870
Background: Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. Aims: To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous...
2.
Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice
Spindler L, Etienney I, Abramowitz L, de Parades V, Pigot F, Siproudhis L, et al.
Tech Coloproctol . 2024 Jan; 28(1):23. PMID: 38198036
In France, about 2000 new cases of anal cancer are diagnosed annually. Squamous cell carcinoma is the most common histological type, mostly occurring secondary to persistent HPV16 infection. Invasive cancer...
3.
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
Poullenot F, Amiot A, Nachury M, Viennot S, Altwegg R, Bouhnik Y, et al.
J Crohns Colitis . 2022 May; 16(10):1523-1530. PMID: 35512337
Introduction: Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the...
4.
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study
Cottron C, Treton X, Altwegg R, Reenaers C, Amiot A, Fumery M, et al.
J Crohns Colitis . 2022 Feb; 16(8):1202-1210. PMID: 35218189
Background And Aims: Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to...
5.
Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID
Buisson A, Filippi J, Amiot A, Cadiot G, Allez M, Marteau P, et al.
J Crohns Colitis . 2020 Dec; 15(6):1000-1008. PMID: 33313808
Background And Aims: Defining and assessing the reproducibility of Crohn's disease [CD] endoscopic lesions is essential in assessing endoscopic healing. Methods: Twelve endoscopic CD experts from the GETAID defined aphthoid...
6.
Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study
Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, et al.
J Crohns Colitis . 2019 Feb; 13(Supplement_1):S616. PMID: 30794285
doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the 'Poster presentations' section of the main abstract book has been withdrawn and re-inserted as DOP63 in the 'Late-breaking abstracts' section.
7.
Outcomes of endoscopic ultrasound-guided biliary drainage: A systematic review and meta-analysis
Hedjoudje A, Sportes A, Grabar S, Zhang A, Koch S, Vuitton L, et al.
United European Gastroenterol J . 2019 Feb; 7(1):60-68. PMID: 30788117
Background: Success and event rates of endoscopic ultrasound (EUS)-guided biliary drainage vary with techniques, and results from different studies remain inconsistent. Objective: We conducted a proportion meta-analysis to evaluate the...
8.
Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study
Briot C, Faure P, Parmentier A, Nachury M, Trang C, Viennot S, et al.
J Crohns Colitis . 2019 Feb; 13(9):1121-1130. PMID: 30785181
Background: Standard high-volume polyethylene glycol [PEG] bowel preparations [PEG-4L] are recommended for patients with inflammatory bowel disease [IBD] undergoing colonoscopy. However, low-volume preparations [≤2 L of active volume] are often...
9.
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, et al.
Aliment Pharmacol Ther . 2017 Dec; 47(4):485-493. PMID: 29250803
Background: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity. Aim: To assess effectiveness of vedolizumab for EIM in patients with inflammatory...
10.
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al.
Aliment Pharmacol Ther . 2017 Jun; 46(3):310-321. PMID: 28593685
Background: We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing...